Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
馬薩諸塞州劍橋，2024年12月18日 /PRNewswire/ -- Blueprint Medicines Corporation（納斯達克：BPMC）今天宣佈，首席執行官Kate Haviland將於2025年1月13日星期一上午9:00（東部時間中午12:00）在第43屆J.P.摩根醫療健康大會上進行公司概述及2025展望的演講。
A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at . A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.
此次演講的直播網絡廣播將可以通過訪問Blueprint Medicines網站的投資者及媒體部分進行觀看。在演講後30天內，網絡廣播的重播將存檔在Blueprint Medicines的網站上。
About Blueprint Medicines
關於Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家全球全方位集成的生物製藥公司，致力於研發能夠改變生命的藥物。我們旨在通過解決兩個核心關注領域的重要醫療問題來減輕人類痛苦：過敏/炎症和腫瘤學/血液學。我們的方法從針對疾病的根本原因開始，利用我們在覈心關注領域的深厚科學知識和跨多種治療手段的藥物發現專業知識。我們在兩種已獲批准的藥物方面擁有成功的記錄，包括我們在美國和歐洲爲系統性肥大細胞增多症(SM)患者帶來的AYVAKIT/AYVAKYt（avapritinib）。憑藉我們建立的研究、開發和商業能力及基礎設施，我們現在的目標是通過推進一系列從早期科學到高級臨床試驗的項目，顯著擴大我們的影響力，這些項目包括肥大細胞疾病（如SM和慢性蕁麻疹）、乳腺癌和其他實體瘤。更多信息，請訪問並在X（前Twitter；@BlueprintMeds）和LinkedIn上關注我們。
Trademarks
商標
Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.
Blueprint Medicines、AYVAKIT、AYVAKYt及相關標誌是Blueprint Medicines Corporation的商標。
SOURCE Blueprint Medicines Corporation
消息來源：Blueprint Medicines Corporation
